Overview
- A senior FDA official confirmed that the agency has opened a retrospective safety study that will analyze hundreds of thousands of mifepristone uses with an interim analysis possible in July.
- The study is designed with a planned interim review and a secondary analysis that will determine the timing and scope of final results.
- Regulators could use the study to impose narrower limits such as new requirements for in-person dispensing, restrictions on mail delivery, or tighter rules on who may prescribe the drug while full withdrawal of approval is seen as legally unlikely.
- The review comes during active litigation over dispensing rules, including a Louisiana challenge that prompted a 5th Circuit order reinstating in-person dispensing and a subsequent Supreme Court decision allowing mail delivery to continue temporarily.
- Any regulatory changes could sharply reduce access for patients who now obtain mifepristone by telehealth or mail, reshape how clinics and telemedicine providers operate, and intensify litigation and political debate over the drug.